The FACS-based cytotoxicity assay of tumor-specific CTLs against EpCAM+ HepG2 cells using lymphocytes from the four treatment groups showed that EpCAM peptide-CTLs increased the cytotoxic activity significantly as the ratio of effectors to targets increased. Here, EPCAM is linked to neoplasm.